Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Experimental nasal influenza vaccine tested in kids, teens
(NIH/National Institute of Allergy and Infectious Diseases) An early-stage clinical trial testing the safety and immune-stimulating ability of an experimental nasal influenza vaccine in healthy 9- to 17-year-old children and teens has begun enrolling participants at a Vaccine and Treatment Evaluation Unit (VTEU) site at Saint Louis University, St. Louis, Missouri. The VTEU is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - September 17, 2018 Category: Infectious Diseases Source Type: news
Scientists develop novel vaccine for lassa fever and rabies
(NIH/National Institute of Allergy and Infectious Diseases) A novel vaccine designed to protect people from both Lassa fever and rabies showed promise in preclinical testing, according to new research published in Nature Communications. The investigational vaccine, called LASSARAB, was developed and tested by scientists at Thomas Jefferson University in Philadelphia; the University of Minho in Braga, Portugal; the University of California, San Diego; and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - October 11, 2018 Category: Infectious Diseases Source Type: news
Genomic analysis offers insight into 2018 Nigeria Lassa fever outbreak
(NIH/National Institute of Allergy and Infectious Diseases) A surge in Lassa fever cases in Nigeria in 2018 doesn't appear to be linked to a single virus strain or increased human-to-human transmission, according to genomic analysis published in NEJM. Multiple institutions collaborated on the report, and the research was supported in part by the National Institute of Allergy and Infectious Diseases, the National Human Genome Research Institute, and the NIH Common Fund's Human Heredity and Health in Africa Program, all components of NIH.
Source: EurekAlert! - Infectious and Emerging Diseases - October 17, 2018 Category: Infectious Diseases Source Type: news
Trial of investigational Ebola treatments begins in Democratic Republic of the Congo
(NIH/National Institute of Allergy and Infectious Diseases) An international team has begun patient enrollment in a clinical trial testing investigational Ebola therapies in the Democratic Republic of the Congo. The randomized, controlled trial is enrolling patients of any age with confirmed Ebola virus disease (DRC). The trial is led and funded by the National Institute for Biomedical Research, part of the DRC Ministry of Health, and the National Institute of Allergy and Infectious Diseases (NIAID).
Source: EurekAlert! - Infectious and Emerging Diseases - November 27, 2018 Category: Infectious Diseases Source Type: news
Meeting the challenge of engaging men in HIV prevention and treatment
(NIH/National Institute of Allergy and Infectious Diseases) A new commentary from National Institutes of Health scientists asserts that engaging men in HIV prevention and care is essential to the goal of ending the HIV pandemic. The article by Adeola Adeyeye, M.D., M.P.A., and David Burns, M.D., M.P.H., of the National Institute of Allergy and Infectious Diseases (NIAID) and Michael Stirratt, Ph.D., of the National Institute of Mental Health (NIMH) also discusses potential solutions.
Source: EurekAlert! - Infectious and Emerging Diseases - November 29, 2018 Category: Infectious Diseases Source Type: news
NIH to fund HIV care and prevention research in vulnerable southern US communities
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases will fund a series of collaborations with medical research institutions in the southern United States to test new ways of implementing HIV treatment and prevention tools in counties with some of the highest rates of new HIV cases nationwide. The US South overall has the highest rates of new HIV diagnoses, people living with HIV, and HIV-related deaths of any US region.
Source: EurekAlert! - Infectious and Emerging Diseases - December 11, 2018 Category: Infectious Diseases Source Type: news
Temperature-stable experimental tuberculosis vaccine enters clinical testing
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 1 human clinical trial is testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis (TB) vaccine. The trial is being conducted at the Saint Louis University School of Medicine Center for Vaccine Development and will enroll healthy adult volunteers. The experimental vaccine, called ID93, was developed by scientists at the Infectious Disease Research Institute in Seattle. The National Institute of Allergy and Infectious Diseases is supporting the trial through a contract to IDRI.
Source: EurekAlert! - Infectious and Emerging Diseases - January 23, 2019 Category: Infectious Diseases Source Type: news
Investigational monoclonal antibody to treat Ebola is safe in adults
(NIH/National Institute of Allergy and Infectious Diseases) The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the NIH Clinical Center in Bethesda, Md. The National Institute of Allergy and Infectious Diseases' Vaccine Research Center developed the investigational treatment and conducted and sponsored the trial.
Source: EurekAlert! - Infectious and Emerging Diseases - January 24, 2019 Category: Infectious Diseases Source Type: news
NIH scientists explore tick salivary glands as tool to study virus transmission, infection
(NIH/National Institute of Allergy and Infectious Diseases) The salivary glands of some tick species could become important research tools for studying how viruses are transmitted from ticks to mammals, and for developing preventive medical countermeasures. Tick salivary glands usually block transmission, but a new study conducted at the National Institute of Allergy and Infectious Diseases at NIH focuses on the role of salivary glands in spreading flaviviruses from black-legged ticks (Ixodes scapularis) to mammals. The new study appears in the journal mBio.
Source: EurekAlert! - Infectious and Emerging Diseases - January 29, 2019 Category: Infectious Diseases Source Type: news
NIH-supported scientists develop tool to measure success of HIV cure strategies
(NIH/National Institute of Allergy and Infectious Diseases) Scientists funded by the National Institutes of Health have developed a new assay to accurately and easily count the cells that comprise the HIV reservoir, the stubborn obstacle to an HIV cure. This advance will enable researchers who are trying to eliminate the HIV reservoir to clearly understand whether their strategies are working. The research was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.
Source: EurekAlert! - Infectious and Emerging Diseases - January 30, 2019 Category: Infectious Diseases Source Type: news
Health care worker sensitivity to chlorhexidine-based hand hygiene solutions: A cross-sectional survey
ConclusionsScreening programs need to identify nurses who develop chlorhexidine sensitivity due to occupational exposure. Strategies to mitigate risk should provide alternatives for those with sensitization.
Source: American Journal of Infection Control - February 12, 2019 Category: Infectious Diseases Source Type: research
NIH trial to track outcomes of liver transplantation from HIV+ donors to HIV+ recipients
(NIH/National Institute of Allergy and Infectious Diseases) The first large-scale clinical trial studying liver transplantation between people with HIV has begun at clinical centers across the US. The HOPE in Action Multicenter Liver Study will determine the safety of this practice by evaluating liver recipients for potential transplant-related and HIV-related complications following surgery. The study is sponsored by the National Institute of Allergy and Infectious Diseases and follows the 2018 launch of a similar study evaluating kidney transplantation between people with HIV.
Source: EurekAlert! - Infectious and Emerging Diseases - February 14, 2019 Category: Infectious Diseases Source Type: news
Acute flaccid myelitis requires galvanized research response
(NIH/National Institute of Allergy and Infectious Diseases) Acute flaccid myelitis (AFM) presents significant challenges not only to patients but also to researchers, and efforts must be accelerated to learn more about the condition, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, write in a new perspective published in mBio.
Source: EurekAlert! - Infectious and Emerging Diseases - April 2, 2019 Category: Infectious Diseases Source Type: news
Opioid epidemic is increasing rates of some infectious diseases
(NIH/National Institute of Allergy and Infectious Diseases) The US faces a public health crisis as the opioid epidemic fuels growing rates of certain infectious diseases, including HIV/AIDS, hepatitis, heart infections, and skin and soft tissue infections. Infectious disease and substance use disorder professionals must work together to stem this public health threat, according to an article co-authored by officials from the National Institute of Allergy and Infectious Diseases and the Institute of Human Virology at the University of Maryland School of Medicine.
Source: EurekAlert! - Infectious and Emerging Diseases - April 3, 2019 Category: Infectious Diseases Source Type: news
NIH researchers make progress toward Epstein-Barr virus vaccine
(NIH/National Institute of Allergy and Infectious Diseases) A research team led by scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) has determined how several antibodies induced by Epstein-Barr virus (EBV), a herpesvirus that causes infectious mononucleosis and is associated with certain cancers, block infection of cells grown in the laboratory. They then used this information to develop novel vaccine candidates that, in animals, elicited potent anti-EBV antibody responses that blocked infection of cell types involved in EBV-associated cancers.
Source: EurekAlert! - Infectious and Emerging Diseases - April 9, 2019 Category: Infectious Diseases Source Type: news
